

Figure S1. Establishment and characterization of HKOs. (A) Bright-field images showing the morphology of hESC at the indicated time points. (B) Bright-field images depicting the morphology of developing HKOs at the indicated time points and stages. (C) qPCR results illustrating the expression of NPHS1, PODXL, ECAD, and GATA3 in HKOs. (D) IF outcome indicating the expression of CK19, ECAD, and PODXL in HKOs. (E) qPCR results illustrating the expression of AQP1 in HKOs.

删除[JH X]:





Figure S2. Optimization of LPS treatment of HKOs. (A-D) qPCR data depicting the expression of IL-1β (A), IL-6 (B), IL-18 (C), and TNF-α (D) in HKOs treated with the indicated concentrations of LPS.



Figure S3. The original gel for Figure 3E Western blot.



Figure S4. The original gel for Figure 5B Western blot.



Figure S5. The original gel for Figure 3G and Figure 5E Western blot.

设置格式[JH X]: 字体: （默认）Times New Roman, 小四, 加粗